Stephanie Bunt, Ph.D.

Managing Director, Healthcare Practice
  (202) 296-2741

Dr. Stephanie Bunt serves as a Managing Director, Healthcare Practice at McAllister & Quinn, where she provides strategic advice to healthcare sector clients by assessing and supporting their funding needs in alignment with their organizational priorities and goals. Stephanie has over 15 years of experience with research, grant writing and management, project and program development, communications, and scientific writing.

Prior to joining McAllister & Quinn, Stephanie spent the previous three years as a Research Assistant Professor, Vice-Chair for Research, and Associate Director of a Practice-Based Research Network (PBRN) in the University of Iowa Department of Family Medicine,  In this role, in addition to her own research, she focused on developing research and strategic initiatives to support department-wide research development and funding initiatives. Prior to this, she spent several years as faculty at the Uniformed Services University as a Director of Research Development for the Military PBRN. Previously, Stephanie worked as a Scientific Grants Manager at Susan G. Komen, where she managed both pre-award and post-award processes, and a large portfolio of over 60 grants. She has also worked in scientific communications and publishing as a Scientific Coordinator at The Journal of Immunology within the American Association of Immunologists.

Stephanie holds a B.S. in Biology from Vanderbilt University and Ph.D. in Biological Sciences from the University of Maryland, Baltimore County, where she specialized in Cancer Immunology. She completed a post-doctoral fellowship at the Eppley Cancer Center at the University of Nebraska Medical Center, where her research focused on breast and pancreas cancer therapeutics. She currently lives in Charleston, SC with her husband, three children, and Goldendoodle.


  1. Bunt SK, Traxler M, Zimmerman B, Rosenbaum M, Heaberlin S, Cronholm P, Kinsey E, Skelly K. Assessing Family Medicine Clinician Screening and Barriers to Communication on Food Insecurity: A CERA General Membership Survey. JABFM. 2024. In Press.
  2. Bunt SK, Bunt CW. Primary Care for Patients with Down Syndrome. STFM and AFMRD Family Medicine Residency Curriculum Resource. 2022.
  3. Bunt CW, Bunt SK. Medical Care for Adults With Down Syndrome: Guidelines from the Global Down Syndrome Foundation. Am Fam Physician. 2022;105(4):436-437.
  4. Bunt CW and Bunt SK. Role of the Family Physician in the care of children with Down Syndrome. Am Fam Physician. 2014 Dec 14; 90(12):851-8. Review.
  5. Bunt SK, Mohr AM, Bailey JM, Grandgenett PM, Hollingsworth MA. “Rosiglitazone and gemcitabine in combination reduces immune suppression and modulates T cell populations in pancreatic cancer.” Cancer Immunol Immunother. 2013 Feb; 62(2):225-36.Featured on the cover.
  6. Radhakrishnan P, Bryant VC, Blowers EC, Rajule R, Gautham N, Anwar MM, Mohr AM, Grandgenett PM, Bunt SK, Arnst JL, Lele SM, Alnouti Y, Hollingsworth MT, Natarajan A. “Targeting the NF-kB and mTOR pathways with a quinoxaline urea analog that inhibits IKKb for pancreas cancer therapy.” Clin Cancer Res. 2013 Apr; 19(8):2025-35.
  7. Radhakrishnan P, Grandgenett PM, Mohr AM, Bunt SK, Yu F, Hollingsworth MA. “Expression of core 3 synthase in human pancreatic cancer cells suppresses tumor growth and metastasis.” Int J Cancer. 2013 Dec; 133(12):2824-33.
  8. Bunt SK, Clements VK, Hanson EM, Sinha P, Ostrand-Rosenberg S. “Inflammation enhances myeloid-derived suppressor cell cross-talk by signaling through Toll-like receptor 4.” J Leukoc Biol. 2009 Jun; 85(6):996-1004.
  9. Bunt SK, Yang L, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. “Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.” Cancer Res. 2007 Oct 15; 67(20):10019-26.
  10. Bunt SK, Hanson EM, Sinha P, Srivastava MK, Clements VK, Ostrand-Rosenberg S. “Tumor-associated Myeloid-derived suppressor cells.”Chapter 19 in Cancer immunotherapy: Immune suppression and tumor growth. Elsevier Inc., Waltham, MA. 2007.
  11. Sinha P, Clements VK, Bunt SK, Albelda SM, Ostrand-Rosenberg S. “Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response.” J Immunol. 2007 Jul 15; 179(2):977-83.
  12. Bunt SK, Sinha P, Clements VK, Leips J, Ostrand-Rosenberg S. “Inflammation induces myeloid-derived suppressor cells that facilitate tumor progression.” J Immunol. 2006 Jan 1; 176(1):284-90.
  13. Rudolph JG, White S, Sokolsky C, Bozak D, Mazzanti C, Lipsky RH, Goldman D. “Determination of melting temperature for variant detection using dHPLC: a comparison between an empirical approach and DNA melting prediction software.” Genet Test. 2002 Fall; 6(3):169-76.


  • Vice-Chair for Research and Scholarship, Dept. of Family Medicine, University of Iowa Associate Director, Practice-based Iowa Research Network
  • Research Assistant Professor, Uniformed Services University of the Health Sciences
  • Scientific Grants Manager, Susan G. Komen


  • Grants
  • Life Sciences
  • Healthcare
  • Research Development



Ph.D., University of Maryland, Baltimore County

B.S., Vanderbilt University